ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 18, 2018 23:00 JST
Source:
LEH Pharma Ltd
LEH Pharma announces first EyeMax Mono surgery performed in Argentina
EyeMax now available in over 25 countries worldwide
Argentina represents significant market opportunity with 5.7 million aged 65 years or older
LONDON, Jun 18, 2018 - (ACN Newswire) - LEH Pharma Ltd, the leading provider of novel ocular implants for macular disorders, today announces that EyeMax Mono lens implant surgery for the treatment of age-related macular degeneration (AMD) has been successfully performed for the first time in Argentina. EyeMax is now being implanted by close to 100 surgeons in over 25 countries around the world.
The EyeMax Mono lens was implanted in both eyes by renowned ophthalmologist Dr Hugo Nano in Buenos Aires, Argentina. The EyeMax lens is the latest in LEH Pharma's AMD lens portfolio and is unique in its ability to improve vision in patients at all stages of both dry and stable wet AMD. The product is delivered through a simple cataract surgery and is CE-marked and approved for sale in 34 countries across Europe and internationally.
AMD affects the central part of the retina and is the leading cause of blindness in people aged over 60, affecting nearly 200 million people worldwide. At present, only limited research has been conducted into the scale of AMD in Latin America, however available data suggests a high number of potential patients. Approximately 54 million people in Latin America and the Caribbean are over 65, and within this Argentina has one of the highest elderly populations in the region with up to 13.1% of the population, or 5.7 million, being 65 years or older1. The unique optics of the EyeMax lens optimises the quality of the image supplied across the macula, permitting patients to make use of functioning areas of retina that would otherwise receive a blurred image. It is the only adequate treatment for all types of AMD.
Dr Hugo Nano said: "It is wonderful to have brought the EyeMax Mono lens into Argentina for the first time. The operation was a success, and this patient will be the first of many to have their quality of life improved by LEH Pharma's technology. AMD is one of the main causes of vision loss in the Argentinian population, so it is exciting to see this new treatment option become available through such a straightforward, quick operation."
Dr Bobby Qureshi, CEO and founder of LEH Pharma, commented: "I am delighted that the EyeMax Mono lens will now be available to patients in Argentina, offering AMD sufferers in the country a chance for improved vision and a better quality of life. This expansion into an important new market underlines our focus on expanding the international reach of our products and services, and creating additional relationships with world-leading surgeons and ophthalmology specialists across the globe."
For more information, please contact:
LEH Pharma Ltd
Dr Bobby Qureshi
contact@LEHPharma.com
+ 44 (0) 20 7060 2763
Consilium Strategic Communications
Mary-Jane Elliott, Ivar Milligan, Chris Welsh
LEHPharma@consilium-comms.com
www.consilium-comms.com
+44 (0) 20 3709 5700
Notes for editors:
About LEH Pharma
LEH Pharma is a leading provider of revolutionary ocular implants for macular disorders. Its disruptive lens technology, which is unique, proven and patented, is currently marketed internationally for the treatment of stable wet and dry AMD. The Company was formed in 2011 by a group of pioneering surgeons, and is supported by a network of world-leading ophthalmologists and scientists. For more information, please visit LEH Pharma's website at www.lehpharma.com
About EyeMax
EyeMax is a revolutionary breakthrough for AMD sufferers and is the only adequate solution for the treatment of both the stable wet and dry form of the condition. EyeMax can be used in both eyes and can be applied fast and easily. The innovative technology and unique optics of the EyeMax lens enhances the quality of the image supplied to the all areas of the macula permitting patients with AMD to make better use of the healthier parts of their retina. Advantages of the product include safer surgery, ease of implantation and significant improvement of vision for patients2. Currently, the only other surgical options available for patients result in sub-optimal vision with high rates of complications. EyeMax is CE-marked in Europe and is exploring FDA approval in the US.
About age related macular degeneration (AMD)
LEH Pharma's EyeMax product is aimed at improving the quality of life of patients with AMD, the western world's biggest cause of blindness and the greatest unmet need in ophthalmology. AMD is a disorder affecting the central part of the retina, causing changes to central vision and making everyday tasks difficult.
EyeMax is aimed at two main patient populations: those who require cataract (where 1 in 3 patients or more may have some form of macular degeneration) and the non-cataract population including patients with AMD prior to cataract surgery or sufferers of other macular diseases such as diabetic eye disease.
2 Published data from several European centres supports the effectiveness of EyeMax and can be found on the website here (www.iolamd.com/clinical-data). Most recently the European Journal of Ophthalmology found EyeMax safe and observed improvements after surgery above those of standard implants.
1 Risk factors of age-related macular degeneration in Argentina; Maria Eugenia Nano et al; April 2013 [Available here
https://bit.ly/2JYrjGG
]
Source: LEH Pharma Ltd
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 09:22 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 16:17 JST
Honda Unveils Next-generation EV Series for China
Apr 17, 2024 12:15 JST
Lexus presents Time at the 2024 Milan Design Week
Apr 16, 2024 18:49 JST
Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA
Apr 16, 2024 14:36 JST
New circuit challenge for TOYOTA GAZOO Racing
Apr 15, 2024 17:21 JST
TOYOTA GAZOO Racing back on asphalt for Croatian challenge
Apr 12, 2024 19:36 JST
Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project
Apr 12, 2024 14:39 JST
MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors
Apr 11, 2024 18:08 JST
Mitsubishi Shipbuilding Acquires Approval in Principle (AiP) from Classification Society ClassNK for Ammonia Fuel Supply System (AFSS)
Apr 11, 2024 17:50 JST
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
Apr 11, 2024 15:10 JST
Mitsubishi Corporation Announces Completion of Capital Raise by Nexamp
Apr 11, 2024 13:07 JST
Mitsubishi Shipbuilding Receives Order for Ammonia Fuel Supply System for Ammonia-Powered Marine Engine
Apr 10, 2024 16:55 JST
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 10, 2024 13:36 JST
More Latest Release >>
Related Release
LEH Pharma appoints two new members to its Scientific Advisory Board
June 13 2018 19:00 JST
LEH Pharma announces appointment of Chairman
May 03 2018 14:00 JST
LEH PHARMA LTD.: Company Update
April 18 2018 20:30 JST
More Press release >>